""	"submission_name"	"submission_date"	"template_name"	"curation_date"	"cohort"	"age_min"	"age_max"	"age_units"	"number_subjects"	"tissue_type"	"tissue_type_term_id"	"response_component_original"	"is_model"	"response_behavior_type"	"response_behavior"	"comparison"	"baseline_time_event"	"time_point"	"time_point_units"	"exposure_material_id"	"additional_exposure_material"	"target_pathogen"	"vaccine_year"	"adjuvant"	"route"	"scheduling"	"publication_reference_id"	"publication_reference_url"	"publication_date"	"signature_source"	"signature_source_url"	"comments"	"response_component"	"response_comp_orig_cnt"	"response_comp_cnt"	"subm_obs_id"	"uniq_obs_id"	"row_key"	"signature_file"	"signature_file_complete"
"subject"	""	""	""	""	""	""	""	""	""	"cell_subset"	""	""	""	""	""	""	""	""	""	"vaccine"	""	"pathogen"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"evidence"	"label"	"label"	"label"	"label"	"label"	"label"	"label"	"label"	"label"	""	"label"	"label"	"label"	"label"	"label"	"label"	"label"	"label"	"label"	""	"label"	""	"label"	"label"	"label"	"label"	"label"	"url"	"label"	"label"	"label"	"label"	""	"label"	"label"	"label"	"label"	"label"	"file"	"file"
"role"	"background"	"background"	"background"	"background"	"observed"	"observed"	"observed"	"observed"	"observed"	"tissue"	"background"	"observed"	"background"	"background"	"measured"	"background"	"background"	"observed"	"observed"	"vaccine"	"background"	"pathogen"	"background"	"background"	"background"	"background"	"background"	"reference"	"background"	"background"	"background"	"background"	""	"observed"	"observed"	"background"	"background"	"background"	"observed"	"observed"
"mime_type"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"numeric_units"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"display_text"	"submission name"	"submission_date"	"template_name"	"curation date"	"Any characteristics of the population(s) studied, plus whether the result was taken from a subgroup of the cohort tested."	"age min."	"age max."	"age units"	"number of subjects"	"tissue type"	"Cell Ontology ID"	"response component (original gene symbol)"	"gene signature is a computed model"	"response behavior type"	"response behavior"	"comparison"	"baseline time"	"time point"	"time point units"	"exposure material vaccine ontology ID (VO)"	"exposure material - additional"	"target pathogen"	"vaccine year (influenza only)"	"adjuvant"	"route"	"scheduling"	"publication reference (PMID)"	"Erwin-Cohen et al. (2012) Host responses to live-attenuated Venezuelan equine encephalitis virus (TC-83): comparison of na√Øve, vaccine responder and nonresponder to TC-83 challenge in human peripheral blood mononuclear cells. Hum Vaccin Immunother. PMID: <a href = 'https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845' target='_blank'>22617845</a>"	"print publication date or posted date if not in print (YYYY-MM-DD or YYYY)"	"signature source figure, table or text section"	"signature source url"	"comments and additional details"	""	"response component (original) count"	"response component count"	"ID of observation within its own submission"	"Uniq ID of observation within its submission type"	"row key"	"response component (genes) file"	" response components including non-HGNC genes"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"OAS1"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"OAS1"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"OAS2"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"OAS2"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"OAS3"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"OAS3"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"IFNB1"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"IFNB1"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"IFIH1"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"IFIH1"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"IRF7"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"IRF7"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"DDX58"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"DDX58"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"TLR3"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"TLR3"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"EIF2AK2"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"EIF2AK2"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"TNF"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"TNF"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"IFNA8"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"IFNA8"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"IFNA4"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"IFNA4"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"IFNA16"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"IFNA16"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"IFNA1"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"IFNA1"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"IFNA14"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"IFNA14"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"IFNA7"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"IFNA7"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"IFNA2"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"IFNA2"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"IFNA21"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"IFNA21"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"IL15"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"IL15"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"CXCL11"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"CXCL11"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"IFIT2"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"IFIT2"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"NEXN"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"NEXN"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"TNFSF10"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"TNFSF10"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"SAMD9L"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"SAMD9L"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"XAF1"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"XAF1"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"CD38"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"CD38"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"HSH2D"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"HSH2D"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"CCRL2"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"CCRL2"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"TCN2"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"TCN2"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"LYN"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"LYN"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"NOD2"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"NOD2"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"CD68"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"CD68"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"EPDR1"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"EPDR1"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
""	"hipc_gene_22617845_6"	"2012.05.24"	"hipc_gene_22617845_6"	""	"subgroup responders (previously immunized)"	"18"	"45"	"years"	""	"peripheral blood mononuclear cell"	"CL:2000001"	"CCR5"	"N"	"gene expression"	"up-regulated"	"24h vs 0h"	"time of challenge infection (PBMCs, in vitro)"	"24"	"hours"	"VO:0004105"	"Live attenuated vaccine TC-83 challenge"	"venezuelan equine encephalitis virus (strain TC-83)"	""	""	""	""	"22617845"	"https://www.ncbi.nlm.nih.gov/pubmed/?term=22617845"	"2012"	"Table 3"	"<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/' target='_blank'>table/T3</a>"	"initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways"	"CCR5"	"39"	"34"	"6"	"110"	"22617845_6_110"	"hipc_gene_sig_22617845_6.txt"	"hipc_gene_sig_complete_22617845_6.txt"
